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A B S T R A C T
Cannabis sativa has been associated with contradictory effects upon seizure states despite its medicinal
use by numerous people with epilepsy. We have recently shown that the phytocannabinoid cannabidiol
(CBD) reduces seizure severity and lethality in the well-established in vivo model of pentylenetetrazole-
induced generalised seizures, suggesting that earlier, small-scale clinical trials examining CBD effects in
people with epilepsy warrant renewed attention. Here, we report the effects of pure CBD (1, 10 and 100 mg/
kg) in two other established rodent seizure models, the acute pilocarpine model of temporal lobe seizure
and the penicillin model of partial seizure. Seizure activity was video recorded and scored ofﬂine using
model-speciﬁc seizure severity scales. In the pilocarpine model CBD (all doses) signiﬁcantly reduced the
percentage of animals experiencing the most severe seizures. In the penicillin model, CBD (10 mg/kg)
signiﬁcantly decreased the percentage mortality as a result of seizures; CBD (all doses) also decreased the
percentage of animals experiencing the most severe tonic–clonic seizures. These results extend the anti-
convulsant proﬁle of CBD; when combined with a reported absence of psychoactive effects, this evidence
strongly supports CBD as a therapeutic candidate for a diverse range of human epilepsies.
 2012 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Dating back to 4000 BC, Cannabis sativa has a long history of
medicinal use for the treatment of a variety of disorders such as
rheumatism, chronic inﬂammation and pain management, in
addition to control of convulsions.1 More recently, C. sativa has
been ascribed both pro-2 and anti-convulsant effects3 despite
numerous people with epilepsy continuing to use C. sativa
medicinally for seizure control.4,5 Since D9-tetrahydrocannabinol
(D9-THC), the major psychoactive constituent of C. sativa was
isolated,6 more than 60 other phytocannabinoids (cannabis-
derived components) have also been identiﬁed, isolated andAbbreviations: D9-THC, D9-tetrahydrocannabinol; AED, anti-epileptic drug; CBD,
cannabidiol; CCTVs, closed-circuit television cameras; CNS, central nervous system;
GABA, g-aminobutyric acid; mAChR, muscarinic acetylcholine receptor; MES,
maximal electroshock; NMDA, N-methyl-D-aspartate; PTZ, pentylenetetrazole; TLE,
temporal lobe epilepsy.
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doi:10.1016/j.seizure.2012.03.001shown to possess varied pharmacological activity.7 One such
phytocannabinoid is cannabidiol (CBD), typically the second most
prevalent phytocannabinoid in C. sativa, whose structure was ﬁrst
described by Mechoulam and Shvo.8 CBD currently represents the
most promising phytocannabinoid candidate for clinical utilisation
due to its non-psychotropic properties, low toxicity and high
tolerability in humans and other animal species.9–11
Early preclinical work demonstrated that CBD possesses anti-
convulsant properties.12–14 In rats, CBD was an effective and
relatively potent anti-convulsant in the maximal electroshock
(MES) and audiogenic seizure models; ﬁndings that compared
favourably with the clinically used AEDs employed in the same
study.15 In mice, CBD pretreatment prevented tonic convulsions
caused by either MES seizures, g-aminobutyric acid (GABA)
antagonists or inhibitors of GABA synthesis, in addition to reliably
protecting against 3-mercaptoproprionic acid-induced lethality.10
Overall, these pre-clinical seizure studies conﬁrmed CBD’s anti-
convulsant proﬁle and are consistent with an assertion of
therapeutic beneﬁts in human epilepsies.
Interestingly and despite these promising pre-clinical results,
only one clinical trial has thus far explored the potential anti-
convulsant effects of CBD in humans.11 Fifteen people experiencing
secondary generalised epilepsy with temporal lobe focus that wasvier Ltd. All rights reserved.
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eight of those receiving CBD in conjunction with their existing
AEDs remained virtually seizure-free during the supplementation
period and the remainder of this patient group exhibited a marked
improvement in seizure control.11 Surprisingly however, no
further clinical trials employing CBD have been published.
The therapeutic potential of the phytocannabinoids attracted
renewed interest following the discovery and characterisation of
the endocannabinoid signalling system that comprises the G
protein-coupled cannabinoid CB1 and CB2 receptors, a family of
endogenous cannabinoid receptor ligands and several enzymes
involved in their metabolism and degradation.16 Whilst a number
of phytocannabinoid actions are mediated via CB1 and/or CB2
receptors,7,17 including the now well-known CB1 receptor-
mediated modulation of epileptiform and seizure activity,18,19
CBD exhibits negligible afﬁnity for either CB1 and/or CB2
receptors.7,20,21 Consequently, it is likely that the anti-convulsant
effects of CBD described above arise via cannabinoid receptor-
independent mechanisms.17,22–24
Recently, we have shown that CBD inhibits epileptiform activity
in vitro and reduces seizure severity and lethality in the
pentylenetetrazole (PTZ) model of generalised seizures in vivo,
strongly supporting reconsideration of the use of CBD in the
treatment of human epilepsies.22 However, in order to strengthen
earlier ﬁndings and inform appropriate human study design,
assessment of the anti-convulsant potential of CBD against
untested seizure phenotypes in vivo is required.
In this present study, we have investigated whether CBD exerts
anti-convulsant effects in the acute pilocarpine-induced model of
temporal lobe seizure and the penicillin-induced model of partial
seizure in rat. Furthermore, four behavioural tests were undertak-
en to assess the effects of CBD on rodent motor function, providing
complementary evidence of CBD’s lack of toxicity.
2. Materials and methods
2.1. Animals
Adult male Wistar Kyoto rats (Harlan, Bicester, UK) were used in
both seizure models and the rotarod test described below (acute
pilocarpine model of temporal lobe seizure: >P21, 70–110 g;
penicillin model of partial seizure: >P40, 250–300 g; motor
function tests: >P28, starting weight 110–140 g). Animals were
housed at room temperature on a 12:12-h day/night cycle (lights
on at 0800) and given ad libitum access to food and water. On days
prior to seizure induction, animals were habituated to handling,
experimental procedures and the test environment. All experi-
ments were carried out in accordance with UK Home Ofﬁce
regulations (Animals (Scientiﬁc Procedures) Act, 1986).
2.2. CBD administration
CBD penetrates the blood–brain barrier such that 120 mg/kg
delivered intraperitoneally in Wistar Kyoto rats provides
Cmax = 6.8 mg/g at Tmax = 120 min and, at the same dosage, no
major toxicity, genotoxicity, or mutagenicity has been observed
(personal communication with GW Pharmaceuticals Ltd.; Study
Report UNA-REP-02). Prior to seizure or motor function protocols,
animals received (i.p.) 1, 10 or 100 mg/kg CBD in all seizure
experiments or 50, 100 or 200 mg/kg CBD in motor function tests
(GW Pharmaceuticals, Porton Down, Wiltshire, UK). The vehicle
employed was a 1:1:18 solution of ethanol, Cremophor (Sigma–
Aldrich, Poole, UK) and 0.9% (w/v) NaCl. In each experiment, a
group of animals that received volume-matched doses of vehicle
alone served as a negative control.2.3. Acute pilocarpine in vivo seizure model
Pilocarpine is a muscarinic acetylcholine receptor agonist that,
following systemic administration, causes localised seizure foci in
the limbic system consistent with temporal lobe seizures25 (n  14
for each group). 15 min after CBD or vehicle administration,
animals were injected with the muscarinic receptor antagonist
methylscopolamine (Sigma–Aldrich, Poole, UK; 1 mg/kg; i.p.) to
minimise peripheral pilocarpine-induced side-effects. 45 min
later, pilocarpine (Sigma–Aldrich, Poole, UK; 380 mg/kg; i.p.)
was administered to induce seizures and animal behaviour was
monitored for a further 60 min. On completion of the experimental
procedure animals were euthanised by CO2 inhalation.
2.4. Penicillin in vivo seizure model
Penicillin selectively antagonises GABAA-receptor mediated
inhibitory postsynaptic potentials in the central nervous system
(CNS).26,27 Surgical implantations of cannulae were required to
enable the focal administration of penicillin G potassium salt
(penicillin; Sigma–Aldrich) directly into the cerebral ventricles to
induce partial seizures.28 Prior to surgery, animals were placed in
an isoﬂurane anaesthetic induction chamber (Vet Tech Solutions
Ltd., Cheshire, UK) which was attached to an isoﬂurane machine
(Vet Tech Solutions Ltd.) with an isoﬂurane vaporiser, oxygen tank
and active scavenging unit. The isoﬂurane (National Veterinary
Services, Stoke on Trent, UK) concentration for induction was set
to 5% and the oxygen ﬂow rate was set to 2 L/min. The
anaesthetised animals were then placed on a stereotaxic frame
(David Kopf, Bilaney Consultants Ltd., Kent, UK) with an
anaesthesia mask (David Kopf Model 906, Bilaney) attached to
the patient breathing circuit of the isoﬂurane machine. Isoﬂurane
concentration was initially 4% before reduction to 3.5% for
maintenance of anaesthesia during the surgery. The oxygen ﬂow
rate was set to 1.5 L/min throughout the surgery. Fucithalmic Vet
(Dechra Veterinary Products A/S, Uldum, Denmark) eye ointment
was applied to the eyes during the surgery. After cranial midline
incision, a 26-gauge guide cannula (Bilaney) was implanted using
ﬂat-skull stereotaxic technique into the right lateral cerebral
ventricle. In all surgeries, bregma was used as a reference point
and implantation co-ordinates were taken from the atlas of
Paxinos and Watson29 (lateromedial: +2.0 mm; anteroposterior:
0.6 mm; dorsoventral: 4.2 mm). After ﬁxation to the skull with
two stainless steel screws (1 mm diameter; Bilaney) and dental
cement (Advanced Healthcare Limited, Kent, UK) each cannula
was sealed with a stylet (Bilaney) to maintain patency. Post-
operatively, buprenorphine hydrochloride (Reckitt Benckiser
Healthcare (UK) Ltd., Hull, UK; 1 mg/kg; s.c.) and 0.9% (w/v) NaCl
(1 ml; s.c.) were administered as required. Animals were housed
individually and allowed at least one week to recover from
surgery.
One hour after CBD administration, 525 IU penicillin was
infused into the right lateral ventricle in 1.5 ml 0.9% (w/v) NaCl to
induce partial seizures (n = 17–18 for each group). Intracerebro-
ventricular infusions were made by attaching the implanted
cannula to a 10 ml Hamilton syringe (Fisher Scientiﬁc, Loughbor-
ough, UK; infusion rate 1.5 ml/min) via a polyethylene tube
(Bilaney). Animal behaviour was then monitored for 120 min after
penicillin administration. On completion of the experimental
procedure, animals were euthanised by CO2 inhalation before
being decapitated. Removed heads were placed in 4% (w/v)
paraformaldehyde (Sigma), left to ﬁx for one week at room
temperature, then dissected and cannula placement conﬁrmed as
right lateral ventricle (conducted blind with respect to seizure
scoring results). Results from any animals which exhibited an
incorrect cannula position were omitted from the study.
Table 1
Severity scoring scale for acute pilocarpine-induced temporal lobe seizures.35
Acute pilocarpine-induced temporal lobe seizures
Seizure score Behavioural expression Righting reﬂex
0 No change in behaviour Preserved
1 Mouth clonus Preserved
2 Unilateral forelimb clonus Preserved
3 Bilateral forelimb clonus Preserved
4 Bilateral forelimb clonus
with rearing and falling
Preserved
5 Tonic–clonic seizure Lost
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An observational system utilising closed-circuit television
cameras (CCTVs)30 was used to monitor the behaviour of up to
ten animals simultaneously and was started prior to CBD
administration. Input from CCTVs was managed on a PC and
recorded by Zoneminder (v1.2.3; Triornis Ltd., Bristol, UK) software
before post-processing to yield complete videos for each animal.
Videos of seizure behaviour were scored ofﬂine according to
modiﬁed seizure severity scales appropriate for the acute
pilocarpine (Table 1; Ref. 31) and penicillin models (Table 2;
adapted from Bostanci and Bagirici28) using Observer Video-Pro
software (Noldus, Wageningen, the Netherlands). Speciﬁc markers
of seizure behaviour and development were assessed and
compared between vehicle control and CBD groups. The percent-
age of animals that developed the two most severe seizure states
was noted for each seizure model (see Tables 1 and 2). In addition,
the mean number of incidences of each state that occurred within
the total recording period was calculated. Finally, the median
severity, the percentage of animals that remained seizure-free
(severity score = 0), and the percentage mortality in each group
was determined for each seizure model.
2.6. Motor function tests
Four behavioural tasks were used to assess motor function after
CBD (50, 100 or 200 mg/kg; i.p.) or vehicle administration. The
motor function of one group of rats (n = 12) was tested on an
accelerating rotarod, whilst a second group (n = 10) was tested on a
static beam task, grip strength task and an inclined screen test.
Each animal received either CBD (50, 100 or 200 mg/kg) or vehicle
on a given experimental day with a rest period of two or more days
between successive treatments. In each case, the order of drug
administration was randomised. The rotarod test commenced one
hour after CBD or vehicle administration. The ﬁrst group of animals
were placed on the rotarod (Panlab/Harvard Apparatus, Holliston,
USA) that linearly increased rotation speed from 4 to 40 rpm
during a 300 s period. An accelerating protocol was employed toTable 2
Modiﬁed severity scoring scale for penicillin-induced partial seizures adapted from
Bostanci and Bagirici.32
Penicillin-induced partial seizures
Seizure score Behavioural expression Righting reﬂex
0 No change in behaviour Preserved
1 Wild running/leaping Preserved
2 Myoclonic phase Preserved
3 Unilateral forelimb clonus Preserved
4 Bilateral forelimb clonus Preserved
4.5 Tonic–clonic seizure with
postural control retained
Preserved
5 Tonic–clonic seizure without
postural control
Losteliminate the need for habituation to the rotarod (based upon
Baytan et al.32). Latency to fall from the rotarod in seconds was
compared between vehicle control and CBD groups to assess motor
function. Each animal undertook three accelerating rotarod runs
per experimental day and was permitted a 5 min recovery between
each run to avoid any fatigue-induced decline in motor perfor-
mance. One hour after CBD or vehicle administration, animals from
the second group were placed at the illuminated, open end of a
100 cm cylindrical static wooden beam (diameter: 32 mm) after
being habituated for ﬁve days to run to the enclosure
(40 cm  40 cm  20 cm) at the other end of the beam. On two
successive occasions separated by a short rest period, animals were
permitted 5 min to traverse the beam. Following a 5 min rest
period, animals then undertook a grip strength test such that
animals gripped a horizontal trapeze bar attached to a digital force
gauge (Sauter FH 50; Scalesmart, Leicester, UK) and were pulled in
a uniform manner until their grip released at which point peak
force (kgf) was recorded. A second trial was performed after a 30 s
rest period. Finally, animals were allowed a 15 min rest period
prior to placement on an inclined screen (6 mm  6 mm mesh; 608
from horizontal; test area 10 cm  43 cm; 100 cm above the ﬂoor).
The animals were placed facing upwards (5 cm from the top edge
of the apparatus). The latency to fall from the screen was recorded,
with a maximum allowed time of 30 min (at which point the
duration of maintenance of grip on the screen was recorded as
1800 s). In all cases, behavioural testing was completed within 1 h
of starting, and therefore within 2 h of CBD administration.
2.7. Statistical analysis
All statistical procedures were performed using SPSS 15.0.0
software (SPSS Inc., Chicago, IL, USA). Differences between groups
for the mean number of occurrences of each seizure state and
median seizure severity values were assessed using one-way
analysis of variance (ANOVA) with a post hoc Tukey test.
Differences between groups in the percentage of animals that
remained seizure-free, percentage of animals that developed the
most severe seizure states and percentage mortality were assessed
using a nonparametric binomial test. Differences between groups
for rotarod performance were assessed using a two-way ANOVA
with ‘latency’ and ‘run’ as factors. Differences between groups in
the proportions of animals that passed the static beam were
assessed using a nonparametric binomial test; differences in mean
numbers of footslips, distance travelled, time taken, grip strength,
and time on inclined screen were assessed by one-way ANOVA
with post hoc Tukey test. In all cases, P  0.05 was considered
signiﬁcant.
3. Results
3.1. Acute pilocarpine model of temporal lobe seizure
In the acute pilocarpine model, all doses of CBD (1, 10 and
100 mg/kg) signiﬁcantly reduced the percentage of animals
manifesting with bilateral forelimb clonus with rearing and falling
(seizure score of 4; Table 1); a reduction from 71% (vehicle-dosed
animals) to 43% following 1 mg/kg CBD (n = 14, P  0.05), 47%
following 10 mg/kg CBD (n = 15, P  0.05), and 29% following
100 mg/kg CBD (n = 14, P  0.01; Fig. 1A). However, despite the
signiﬁcant reduction in the number of animals exhibiting this
seizure state, no signiﬁcant CBD effect upon the mean number of
occurrences for each animal of this state was seen at any dose
(F3,56 = 0.575, P = 0.634; Fig. 1B). Thus, although CBD signiﬁcantly
decreased the percentage of animals exhibiting bilateral forelimb
clonus with rearing and falling, it did not signiﬁcantly decrease the
number of occurrences.
Fig. 1. Cannabidiol (CBD) attenuates acute pilocarpine-induced temporal lobe seizures. Percentage reaching: (A) bilateral forelimb clonus with rearing and falling seizures, (C)
tonic–clonic seizures. Mean number of occurrences: (B) bilateral forelimb clonus with rearing and falling seizures, (D) tonic–clonic seizures. Each data set n  14 animals.
Statistical testing was performed using either a binomial test (panels A and C) or one-way ANOVA with post hoc Tukey test (panels B and D). *P < 0.05, **P < 0.01. n = 15 for all
groups.
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decrease in the percentage of animals that developed this most
severe state (seizure score 5; Table 1), which was reduced from 86%
in vehicle-dosed animals to 64% following 1 mg/kg CBD treatment
(n = 14, P  0.05) and 57% following 100 mg/kg CBD treatment
(n = 14, P  0.01). However, no reduction in the percentage of
animals that developed tonic–clonic seizures was seen following
10 mg/kg CBD treatment (87%; P > 0.1; Fig. 1C). CBD signiﬁcantly
reduced the occurrence of tonic–clonic seizure state seizures at all
doses (F3,56 = 5.306, P = 0.003). For individual CBD doses, occur-
rence was decreased from 3.4  0.7 in vehicle-dosed animals to
1.4  0.4 following 1 mg/kg CBD treatment (n = 14, P  0.05),
1.7  0.2 following 10 mg/kg CBD treatment (n = 15, P  0.05) and
1.2  0.4 following 100 mg/kg CBD treatment (n = 14, P  0.01;
Fig. 1D). Thus, administration of 1 mg/kg and 100 mg/kg CBD
signiﬁcantly reduced the percentage of animals exhibiting tonic–
clonic seizures, whilst CBD administration at all doses signiﬁcantly
reduced the mean number of occurrences of those animals reaching
this state.
In contrast, 1 and 100 mg/kg CBD had no effect on percentage
mortality when compared to vehicle (P > 0.1), although 10 mg/kg
CBD signiﬁcantly increased percentage mortality (n = 15, P  0.05).
However, when the severity of pilocarpine-induced seizures is
considered, CBD had neither a pro- nor anti-convulsant effect as all
animal groups reached a median severity score of 5 (F3,56 = 1.902,
P = 0.140). Furthermore, no CBD doses had an effect on the
percentage of animals that remained seizure-free, with all animals
experiencing a pilocarpine-induced seizure event during the
experiment.3.2. Penicillin model of partial seizure
An analysis of seizure severity in penicillin-treated animals
revealed that vehicle-dosed animals reached a median seizure
severity score of 5 (tonic–clonic seizure without postural control;
the most severe on the scoring scale; Table 2) (Fig. 2A), whilst in
groups that received 10 or 100 mg/kg CBD the median decreased to
4.5 (tonic–clonic seizure maintaining postural control; Table 2)
due to the greater number of animals with more moderate seizures
compared to the vehicle group, although this was not signiﬁcant
(Fig. 2A; P > 0.1). Similarly, no effect of CBD treatment on the
proportion of animals that remained seizure-free was observed
(P > 0.1; Fig. 2B). However, CBD treatment (10 mg/kg) did cause
signiﬁcant reductions in the percentage mortality of animals
exhibiting penicillin-induced partial seizures (P  0.001 for both
doses; Fig. 2C). Whilst no overall effect on severity was seen, the
percentage of animals that developed tonic–clonic seizures whilst
retaining postural control (seizure score 4.5; Table 2) was
signiﬁcantly decreased by all CBD doses; 94% of vehicle treated
animals exhibited this seizure behaviour; this was reduced to 76%
(P  0.05), 61% (P  0.001) and 59% (P  0.001) by treatment with
1, 10 and 100 mg/kg CBD respectively (Fig. 3A). Despite the
reduction in the number of animals exhibiting tonic–clonic
seizures with retained postural control, CBD did not affect the
mean number of occurrences of this state (F3,68 = 0.830, P > 0.1)
(Fig. 3B). Therefore, despite the percentage of animals exhibiting
this state decreasing, those that reached this state after CBD
treatment exhibited the same number of occurrences as vehicle-
dosed animals.
Fig. 2. Cannabidiol (CBD) attenuates penicillin-induced partial seizures. (A) Median seizure severity. Grey lines show median severity, black boxes show 25th and 75th
percentiles and error bars indicate 0th and 100th percentiles. (B) Percentage of seizure-free animals. (C) Percentage mortality. Statistical testing was performed using either a
binomial test (panels B and C) or one-way ANOVA with post hoc Tukey test (panel A). *P < 0.05, ***P < 0.001. n = 17–18 per group.
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seizures without postural control (seizure score 5; Table 2),
revealed a marked decrease in the percentage of animals that
developed this most severe state which was reduced from 82% in
vehicle-dosed animals to 50% after 10 mg/kg CBD (P  0.001) and
47% following 100 mg/kg CBD (P  0.001; Fig. 3C). No effect of CBD
was observed on the mean number of occurrences of tonic–clonic
seizures without postural control (F3,68 = 2.162, P > 0.1; Fig. 3D).
Thus CBD decreases both the lethality of penicillin-induced
seizures and the proportion of animals that developed the most
severe seizures.
3.3. Motor function tests
In the accelerating rotarod test, CBD (50, 100 or 200 mg/kg) had
no effect on the latency to fall when compared to vehicle-dosed
animals (F3,99 = 0.568, P = 0.637; Fig. 4A). Furthermore, no signiﬁ-
cant differences between runs were found (F2,33 = 1.378, P = 0.266)
nor was any signiﬁcant interaction between drug and run found
(F6,99 = 0.284, P = 0.943). The percentage of animals that success-
fully traversed the static beam was not signiﬁcantly affected by
CBD treatment (P > 0.1; Fig. 4B). CBD did however have a
signiﬁcant effect on the mean number of footslip errors that rats
made (F3,79 = 2.915, P  0.05; Fig. 4C), which was apparent only at
100 mg/kg CBD (P  0.05). The effect of CBD on footslips however
had no signiﬁcant impact on the average time taken for animals to
traverse the static beam (vehicle: 11.8  2.6 s; 50 mg/kg:
11.2  2.9 s; 100 mg/kg: 19.1  5.2 s; 200 mg/kg: 9.8  2.8 s;
F3,74 = 1.405, P > 0.1). Similarly, CBD treatment had no effect on
the average distance completed (vehicle: 98.5  1.5 cm; 50 mg/kg:
97.5  2.5 cm; 100 mg/kg: 90.5  5.6 cm; 200 mg/kg: 100 cm;F3,79 = 1.758, P > 0.1). The grip strength test was used to assess
effects of CBD treatment on muscle strength; it is also a putative test
for functional neurotoxicity.33,34 CBD treatment had no effect on the
mean grip strength of rats (Fig. 4D; F3,79 = 0.115, P > 0.1). Muscle
tone, as assessed by the inclined screen test, was also unaffected by
CBD treatment, with no signiﬁcant difference in the duration animals
remained on the screen being observed between any group (vehicle,
100 mg/kg and 200 mg/kg: 180 0s; 50 mg/kg: 1748.1  42.1 s;
F3,39 = 1.522, P > 0.1). These data indicate that, overall, CBD had very
little effect on motor function that may compromise data indicating
that CBD is an anti-convulsant collected in this study.
4. Discussion
In the present study, we examined the anti-convulsant
potential of CBD, the most prevalent non-psychoactive phytocan-
nabinoid found in C. sativa, in models of temporal lobe and partial
seizures. In the acute pilocarpine model, CBD showed modest anti-
convulsant effects, signiﬁcantly lowering the incidence of the most
severe seizures. However, these ﬁndings were not reﬂected in
effects on mortality and severity. By contrast, strong anti-
convulsant CBD effects were seen in the penicillin model of
partial seizure. CBD signiﬁcantly reduced mortality and signiﬁ-
cantly lowered the percentage of animals experiencing tonic–
clonic seizures both with and without maintained postural control.
Furthermore, four separate tests of motor function and muscle
strength and tone indicated that CBD exerted only limited effects
on motor function. Thus, here we demonstrate CBD’s potential as a
novel AED in temporal lobe and partial seizures, complementing
previous research in other in vivo animal models.15,20,27
Fig. 3. Effects of cannabidiol (CBD) on penicillin-induced partial tonic–clonic seizures. Percentage of animals reaching: (A) tonic–clonic seizures with retained postural
control, (C) tonic–clonic seizures without postural control. Mean (S.E.M.) number of occurrences: (B) tonic–clonic seizures with retained postural control, (D) tonic–clonic
seizures without postural control. n = 17–18 animals per group. Statistical testing was performed using either a binomial test (panels A and C) or one-way ANOVA with post hoc
Tukey test (panels B and D). *P < 0.05, ***P < 0.001. n = 17–18 per group.
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In the temporal lobe model, acute pilocarpine-induced seizure
development is thought to be dependent on the activation of the
muscarinic acetylcholine receptor (mAChR) M1 subtype since
M1R/mice do not develop seizures in response to pilocarpine.35
However, once initiated, seizure maintenance is dependent on N-
methyl-D-aspartate (NMDA) receptor activation, and centrally
acting muscarinic antagonists (e.g. atropine) fail to abolish
pilocarpine-induced seizures.36 Although CBD did not reduce
mortality in the acute pilocarpine model, this could be a
consequence of the well-reported high mortality rate associated
with this model37–40 which is attributed to an increased likelihood
of respiratory failure associated with severe tonic–clonic seizure
states compared to other models. Moreover, any respiratory
depression could obscure or confound potentially mitigating drug
effects upon mortality. Conversely, the lack of CBD effects upon
other parameters could also have occurred as a result of CBD
lacking activity against the initiation of seizures induced by
pilocarpine, which is via M1 mAChR activation. Since CBD
signiﬁcantly reduced the number of occurrences of tonic–clonic
seizures but did not affect seizure initiation, it is possible that
CBD’s anti-convulsant effects mitigate against NMDAR-mediated
maintenance, but not mAChR-mediated initiation of acute
pilocarpine-induced seizures.
In models of temporal lobe epilepsy (TLE), manifestation of the
more severe seizure states (e.g. tonic–clonic seizures) is correlated
with the eventual development of spontaneous recurrent excita-
tion.41 Consequently, the CBD-induced reduction in the percentage
of animals developing such severe seizure states suggests thatfurther investigation of CBD effects in the chronic pilocarpine
model of spontaneously recurrent seizures is warranted. This
assessment of CBD against spontaneous recurrent and secondarily
generalised seizures modelled on TLE may prove worthwhile as
Cunha and colleagues11 reported beneﬁcial CBD effects in people
with secondary generalised epilepsy with a temporal lobe focus. A
signiﬁcant co-morbidity associated with epilepsy is depression.
Serotonin dysfunction has been implicated in depression in people
without epilepsy,42 and has also been described as a possible
causative factor in depression associated with epilepsy (for
reviews see Refs. 43,44). CBD could therefore also hold additional
beneﬁts for people with TLE that exhibit a high co-morbid
association with depression as a result of decreased serotonergic
function,45,46 as CBD as shown agonistic properties at 5-HT1A
receptors in vitro resulting in increased serotonergic function,
albeit at concentrations of >10 mM.47 Additionally, CBD has
exhibited signiﬁcant anti-depressant-like effects in the forced
swim and tail suspension tests, without changing the exploratory
behaviour of Swiss mice in vivo.48,49 In future, CBD should be tested
for anti-depressant-like effects on behaviour in epileptic animals
(as in e.g. Ref. 50) to investigate whether this potential beneﬁt
translates in an epileptic phenotype.
4.2. Penicillin model of partial seizure
In the penicillin model of partial seizure, penicillin administra-
tion into a cerebral ventricle leads to the local suppression of
GABA-mediated inhibitory neurotransmission (overall causing
disinhibition of the local circuitry) and, consequentially, partial
seizures. In the present study, we have shown that CBD (10 mg/
Fig. 4. Effects of CBD treatment on motor performance. (A) Box plot showing the latency to fall for vehicle and CBD (50, 100 and 200 mg/kg) treated animals on the accelerating
rotarod test for motor function. Grey lines show median latency to fall from the rotarod, black boxes show 25th and 75th percentiles and error bars indicate 10th and 90th
percentiles. n = 12 animals. Statistical testing was performed using a two-way ANOVA, revealing no signiﬁcant differences in motor function. (B) Percentage passing static
beam test. (C) Mean number of footslips per animal observed on static beam test (S.E.M.). (D) Mean grip strength of rats (S.E.M.; kilograms of force, kgf). (B and C) n = 10
animals, two values from each animal per group. (D) n = 10 animals. Statistical testing in (A) was performed using a two-way ANOVA, revealing no signiﬁcant differences in motor
function; in (B) by binomial test and in (C) and (D) by one-way ANOVA with post hoc Tukey test. *P < 0.05.
N.A. Jones et al. / Seizure 21 (2012) 344–352350kg) exerts clear anti-convulsant effects with signiﬁcant reductions
in the lethality of seizures and the proportions of animals
developing the most severe (tonic–clonic) seizure types. The
anti-convulsant effects in this model are comparable to data
previously reported, showing CBD (100 mg/kg) to be effective in
the PTZ model of generalised seizure.22 Previously, Consroe and
colleagues using several other seizure models found CBD to be
exerting an anti-convulsant effect via the disinhibition of GABA,
resulting in a proposed GABA-related mechanism of action.10
Therefore, CBD could also be exerting its beneﬁcial effects here in
the penicillin model through the same GABA related mechanism of
action. However, this provides only an indirect assessment, so
further investigation is therefore required before deﬁnitive
mechanistic conclusions regarding CBD’s anti-convulsant effects
can be drawn.
4.3. Motor function tests
Although CBD has previously been reported to be devoid of
motor side-effects,9–11 we investigated CBD effects upon perfor-
mance in a variety of motor tasks. With the exception of an effect of
100 mg/kg CBD on the number of footslips as animals traversed a
static beam, no effect of CBD treatment on motor function was
observed in this study. Footslips on the static beam apparatus have
been reported to correlate with deﬁcits in sensorimotor coordina-
tion,51 however the effect of 100 mg/kg CBD on footslips did not
affect the ability of animals to complete the test, or their speed onthe beam, and was not reﬂected in a poor performance on the
rotarod. CBD also had no effect on grip strength, which represents
both muscle strength and can be used as a measure of functional
neurotoxicity,33,34 or muscle tone as assessed by the inclined
screen. Thus, we have demonstrated that CBD had minimal effects
on motor function at doses up to 200 mg/kg. In contrast, all AEDs
licensed for clinical use in the UK cause signiﬁcant and strong
motor side-effects emphasising the advantage of CBD as a potential
clinical anti-convulsant.52
4.4. Mechanisms
The speciﬁc cellular mechanisms underlying lethality in both
the pilocarpine and penicillin models are unknown, so we are
presently unable to rationalise the observed CBD-induced reduc-
tion in mortality in the penicillin model of seizure only. However,
CBD has a signiﬁcant anti-convulsant effect by reducing the
percentage of animals developing the most severe tonic–clonic
seizure states in both models employed. Therefore, in these
models, CBD may act preferentially to reduce seizure spread
irrespective of its focal origin in the brain.10 Moreover, if CBD is
indeed preventing seizure spread, this is unlikely to also affect
normal biophysical signal propagation, as demonstrated by our
previous ﬁndings in in vitro hippocampal brain slice models of
‘‘epileptiform’’ activity,22 where CBD did not affect the speed of
signal propagation but did attenuate chemically induced seizure-
like activity. This further supports the positive side-effect proﬁle of
N.A. Jones et al. / Seizure 21 (2012) 344–352 351CBD,9–11 which is not shared by most clinically used AEDs.
Consistent with our previous ﬁndings,22 CBD appears to hold the
greatest potential for the treatment of partial and generalised
seizures, rather than temporal lobe seizures. It is already well
known that CBD has only very low afﬁnity for both endogenous CB1
and CB2 receptors
7,20,21 and is therefore likely to be exerting its
anti-convulsant activity via cannabinoid receptor-independent
mechanisms.17,22,23
Thus far, CBD has shown a poly-pharmacological proﬁle,
potentially modulating neuronal hyperexcitability via a number
of different mechanisms (see also Jones et al.22). In this regard,
proposed mechanisms include: (1) the bidirectional regulation of
Ca2+ homeostasis via the mitochondrial Na+/Ca2+-exchanger to
either elevate or decrease cytosolic Ca2+ levels, dependent on
whether the neuron is under normal physiological or a highly
excitable state53; (2) agonistic properties at 5-HT1A receptors,
47,54–
56 with receptor activation eliciting membrane hyperpolarising
responses, consistent with an inhibitory role in seizure genera-
tion46,57; (3) enhancing endogenous adenosine levels in the CNS by
reducing adenosine reuptake,58,59 thereby increasing inhibitory
adenosinergic tone to aid seizure suppression. Moreover, numer-
ous additional cellular and molecular CBD effects and mechanisms
of action have also been proposed, but are less likely to be related
to CBD’s anti-convulsant proﬁle but, for example, have pharmaco-
logical relevance in CNS disorders, pain, inﬂammation and cancer
(reviewed in Hill et al.24 and Izzo et al.60). In summary, CBD’s anti-
convulsant effects may not be due to be one speciﬁc mechanism of
action but the result of numerous cannabinoid receptor-indepen-
dent mechanisms. The understanding of these mechanisms of
action will be critical to improve CBD’s efﬁcacy, safety proﬁle and
to enhance drug combination strategies for this potential anti-
convulsant in the future.
4.5. Therapeutic potential
We propose that CBD exerts a cumulative anti-convulsant
effect; this may be achieved by a poly-pharmacological proﬁle,
with CBD simultaneously modulating a number of endogenous
systems to attenuate and/or prevent epileptic neuronal hyperex-
citability. Importantly, despite numerous potential targets, CBD
has an excellent side-effect proﬁle, as revealed in this investigation
and others.9–11 Moreover, CBD may have attractive synergistic or
additive effects when co-administered with currently prescribed
AEDs, noting that it is compulsory for new therapeutic agents to
ﬁrstly be co-administered with currently available AEDs. There-
fore, adjunctive CBD treatment may potentially have beneﬁcial
effects as an anti-convulsant, as well as decreasing the necessary
dose, and therefore the undesirable side-effects of current AED
treatments.
5. Conclusions
Overall, we demonstrate the anti-convulsant actions of CBD for
the ﬁrst time in the acute pilocarpine and penicillin models of
temporal lobe and partial seizures respectively. These results
clearly extend previously published data from other in vivo models
which point to CBD being of potential therapeutic use (alone or as
an adjunct) in the treatment of epilepsies. Future research is now
required to investigate the potential synergistic or additive effects
of CBD on AEDs and to establish in greater detail this important
phytocannabinoid’s anti-convulsant mechanism(s) of action.
Conﬂict of interest statement
YY and SA are employees of Otsuka Pharmaceuticals. The
experimental design was by NAJ, CMW, BJW and AJH.Acknowledgements
The authors thank GW Pharmaceuticals and Otsuka Pharma-
ceuticals for funding and Miss P. Rummings and her team for their
technical assistance.
References
1. Li HL. An archaeological and historical account of cannabis in China. Economic
Botany 1974;28:437–48.
2. Brust JC, Ng SK, Hauser AW, Susser M. Marijuana use and the risk of new onset
seizures. Transactions of the American Clinical and Climatological Association
1992;103:176–81.
3. Gross DW, Hamm J, Ashworth NL, Quigley D. Marijuana use and epilepsy:
prevalence in patients of a tertiary care epilepsy center. Neurology
2004;62(11):2095–7.
4. Schnelle M, Grotenhermen F, Reif M, Gorter RW. Results of a standardized
survey on the medical use of cannabis products in the German-speaking area.
Forschende Komplementarmedizin 1999;6(Suppl. 3):28–36.
5. Wingerchuk D. Cannabis for medical purposes: cultivating science, weeding out
the ﬁction. Lancet 2004;364:315–6.
6. Gaoni Y, Mechoulam R. Isolation, structure, and partial synthesis of an active
constituent of hashish1. Journal of the American Chemical Society 1964;86(8):
1646–7.
7. Pertwee RG. The diverse CB1 and CB2 receptor pharmacology of three plant
cannabinoids: Delta 9-tetrahydrocannabinol, cannabidiol and Delta 9-tetrahy-
drocannabivarin. British Journal of Pharmacology 2008;153:199–215.
8. Mechoulam R, Shvo Y. Hashish—I. The structure of cannabidiol. Tetrahedron
1963;19(12):2073–8.
9. Bhattacharyya S, Fusar-Poli P, Borgwardt S, Martin-Santos R, Nosarti C, O’Carroll
C, et al. Modulation of mediotemporal and ventrostriatal function in humans by
{Delta} 9-tetrahydrocannabinol: a neural basis for the effects of Cannabis sativa
on learning and psychosis. Archives of General Psychiatry 2009;66(4):442–51.
10. Consroe P, Benedito MAC, Leite JR, Carlini EA, Mechoulam R. Effects of canna-
bidiol on behavioral seizures caused by convulsant drugs or current in mice.
European Journal of Pharmacology 1982;83(3–4):293–8.
11. Cunha JM, Carlini EA, Pereira AE, Ramos OL, Pimentel C, Gagliardi R, et al.
Chronic administration of cannabidiol to healthy volunteers and epileptic
patients. Pharmacology 1980;21(3):175–85.
12. Carlini EA, Leite JR, Tannhauser M, Berardi AC. Letter: cannabidiol and Cannabis
sativa extract protect mice and rats against convulsive agents. The Journal of
Pharmacy and Pharmacology 1973;25(8):664–5.
13. Izquierdo I, Orsingher OA, Berardi AC. Effect of cannabidiol and of other
Cannabis sativa compounds on hippocampal seizure discharges. Psychophar-
macology 1973;28(1):95–102.
14. Karler R, Cely W, Turkanis SA. The anticonvulsant activity of cannabidiol and
cannabinol. Life Sciences 1973;13(11):1527–31.
15. Consroe P, Wolkin A. Cannabidiol–antiepileptic drug comparisons and inter-
actions in experimentally induced seizures in rats. Journal of Pharmacology and
Experimental Therapeutics 1977;201(1):26–32.
16. Di Marzo V. Targeting the endocannabinoid system: to enhance or reduce?
Nature Reviews Drug Discovery 2008;7(5):438–55.
17. Howlett AC, Breivogel CS, Childers SR, Deadwyler SA, Hampson RE, Porrino LJ.
Cannabinoid physiology and pharmacology: 30 years of progress. Neurophar-
macology 2004;47:345–58.
18. Shen M, Thayer SA. 9-Tetrahydrocannabinol acts as a partial agonist to modu-
late glutamatergic synaptic transmission between rat hippocampal neurons in
culture. Molecular Pharmacology 1999;55(1):8–13.
19. Wallace MJ, Wiley JL, Martin BR, DeLorenzo RJ. Assessment of the role of CB1
receptors in cannabinoid anticonvulsant effects. European Journal of Pharma-
cology 2001;428(1):51–7.
20. Bisogno T, Hanusˇ L, De Petrocellis L, Tchilibon S, Ponde DE, Brandi I, et al.
Molecular targets for cannabidiol and its synthetic analogues: effect on vanil-
loid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of
anandamide. British Journal of Pharmacology 2001;134(4):845–52.
21. Rhee MH, Vogel Z, Barg J, Bayewitch M, Levy R, Hanus L, et al. Cannabinol
derivatives: binding to cannabinoid receptors and inhibition of adenylylcy-
clase. Journal of Medicinal Chemistry 1997;40(20):3228–33.
22. Jones NA, Hill AJ, Smith I, Bevan SA, Williams CM, Whalley BJ, et al. Cannabidiol
displays antiepileptiform and antiseizure properties in vitro and in vivo. Journal
of Pharmacology and Experimental Therapeutics 2010;332(2):569–77.
23. Ryberg E, Larsson N, Sjo¨gren S, Hjorth S, Hermansson N. The orphan receptor
GPR55 is a novel cannabinoid receptor. British Journal of Pharmacology
2007;152(7):1092–101.
24. Hill AJ, Williams CM, Whalley BJ, Stephens GJ. Phytocannabinoids as novel
therapeutic agents in CNS disorders. Pharmacology & Therapeutics 2012;133(1):
79–97.
25. Bartolomei F, Khalil M, Wendling F, Sontheimer A, Re´gis J, Ranjeva JP, et al.
Entorhinal cortex involvement in human mesial temporal lobe epilepsy: an
electrophysiologic and volumetric study. Epilepsia 2005;46(5):677–87.
26. Dingledine R, Gjerstad L. Reduced inhibition during epileptiform activity in the
in vitro hippocampal slice. The Journal of Physiology 1980;305(1):297–313.
27. Wong RK, Prince DA. Dendritic mechanisms underlying penicillin-induced
epileptiform activity. Science 1979;204(4398):1228–31.
N.A. Jones et al. / Seizure 21 (2012) 344–35235228. Bostanci M, Bagirici F. Anticonvulsive effects of quinine on penicillin-induced
epileptiform activity: an in vivo study. Seizure 2007;16(2):166–72.
29. Paxinos G, Watson C. The rat brain in stereotaxic coordinates. Sydney: Academic
Press; 1982.
30. Farrimond JA, Hill AJ, Jones NA, Stephens GJ, Whalley BJ, Williams CM. A cost-
effective high-throughput digital system for observation and acquisition of
animal behavioral data. Behavior Research Methods 2009;41(2):446–51.
31. Cavalheiro EA, Naffah-Mazzacoratti MG, Mello LE, Leite JP. The pilocarpine
model of seizures. In: Pitka¨nen A, Schwartzkroin PA, Moshe SL, editors. Models
of seizures and epilepsy. London: Elsevier Academic Press; 2006. p. 433–48.
32. Baytan SH, Alkanat M, Okuyan M, Ekinci M, Gedikli E, Ozeren M, et al.
Simvastatin impairs spatial memory in rats at a speciﬁc dose level. The Tohoku
Journal of Experimental Medicine 2008;214(4):341–9.
33. Crofton KM, Padilla S, Tilson HA, Anthony DC, Raymer JH, MacPhail RC. The
impact of dose rate on the neurotoxicity of acrylamide: the interaction of
administered dose, target tissue concentrations, tissue damage, and functional
effects. Toxicology and Applied Pharmacology 1996;139(1):163–76.
34. Nevins ME, Nash SA, Beardsley PM. Quantitative grip strength assessment as a
means of evaluating muscle relaxation in mice. Psychopharmacology (Berl)
1993;110(1–2):92–6.
35. Hamilton SE, Loose MD, Qi M, Levey AI, Hille B, McKnight GS, et al. Disruption of
the m1 receptor gene ablates muscarinic receptor-dependent M current regu-
lation and seizure activity in mice. Proceedings of the National Academy of
Sciences of the United States of America 1997;94(24):13311–6.
36. Clifford DB, Olney JW, Maniotis A, Collins RC, Zorumski CF. The functional
anatomy and pathology of lithium-pilocarpine and high-dose pilocarpine
seizures. Neuroscience 1987;23(3):953–68.
37. Esclapez M, Hirsch JC, Ben-Ari Y, Bernard C. Newly formed excitatory pathways
provide a substrate for hyperexcitability in experimental temporal lobe epi-
lepsy. Journal of Comparative Neurology 1999;408(4):449–60.
38. Gofﬁn K, Nissinen J, Van Laere K, Pitka¨nen A. Cyclicity of spontaneous recurrent
seizures in pilocarpine model of temporal lobe epilepsy in rat. Experimental
Neurology 2007;205(2):501–5.
39. Leite JP, Bortolotto ZA, Cavalheiro EA. Spontaneous recurrent seizures in rats: an
experimental model of partial epilepsy. Neuroscience & Biobehavioral Reviews
1991;14(4):511–7.
40. Sharma AK, Reams RY, Jordan WH, Miller MA, Thacker HL, Snyder PW. Mesial
temporal lobe epilepsy: pathogenesis, induced rodent models and lesions.
Toxicologic Pathology 2007;35(7):984–99.
41. Bhaskaran MD, Smith BN. Effects of TRPV1 activation on synaptic excitation in
the dentate gyrus of a mouse model of temporal lobe epilepsy. Experimental
Neurology 2010. 10.1016/j.expneurol.2010.01.021.
42. Ressler KJ, Nemeroff CB. Role of serotonergic and noradrenergic systems in the
pathophysiology of depression and anxiety disorders. Depression and Anxiety
2000;12(Suppl. 1):2–19.
43. Hecimovic H, Salpekar J, Kanner AM, Barry JJ. Suicidality and epilepsy: a
neuropsychobiological perspective. Epilepsy and Behavior 2011;22:77–84.44. Richerson GB, Buchanan GF. The serotonin axis: shared mechanisms in seizures,
depression and SUDEP. Epilepsia 2011;52(Suppl. 1):28–38.
45. Edeh J, Toone B. Relationship between interictal psychopathology and the type
of epilepsy. Results of a survey in general practice. The British Journal of
Psychiatry 1987;151(1):95–101.
46. Theodore WH. Does serotonin play a role in epilepsy? Epilepsy Currents
2003;3(5):173–7.
47. Russo EB, Burnett A, Hall B, Parker KK. Agonistic properties of cannabidiol at 5-
HT1a receptors. Neurochemical Research 2005;30(8):1037–43.
48. El-Alfy AT, Ivey K, Robinson K, Ahmed S, Radwan M, Slade D, et al. Antidepres-
sant-like effect of delta9-tetrahydrocannabinol and other cannabinoids isolat-
ed from Cannabis sativa L.. Pharmacology Biochemistry and Behavior 2010;95(4):
434–42.
49. Zanelati TV, Biojone C, Moreira FA, Guimaraes FS, Joca SR. Antidepressant-like
effects of cannabidiol in mice: possible involvement of 5-HT1A receptors.
British Journal of Pharmacology 2010;159(1):122–8.
50. Russo E, Citraro R, Scicchitano F, Urzino A, Marra R, Rispoli V, et al. Vigabatrin
has antiepileptogenic and antidepressant effects in an animal model of
epilepsy and depression comorbidity. Behavioural Brain Research 2011;225(1):
373–6.
51. Martin J. British national formulary. 59th ed. London: Pharmaceutical Press;
2010.
52. Yu FH, Catterall WA. Overview of the voltage-gated sodium channel family.
Genome Biology 2003;4(3):207.
53. Ryan D, Drysdale AJ, Lafourcade C, Pertwee RG, Platt B. Cannabidiol targets
mitochondria to regulate intracellular Ca2+ levels. Journal of Neuroscience
2009;29(7):2053–63.
54. Andrade R, Nicoll RA. Pharmacologically distinct actions of serotonin on single
pyramidal neurones of the rat hippocampus recorded in vitro. The Journal of
Physiology 1987;394(1):99–124.
55. Segal M. The action of serotonin in the rat hippocampal slice preparation. The
Journal of Physiology 1980;303(1):423–39.
56. Sprouse JS, Aghajanian GK. Electrophysiological responses of serotoninergic
dorsal raphe neurons to 5-HT1A and 5-HT1B agonists. Synapse 1987;1(1):
3–9.
57. Merlet I, Ostrowsky K, Costes N, Ryvlin P, Isnard J, Faillenot I, et al. 5-HT1A
receptor binding and intracerebral activity in temporal lobe epilepsy: an [18F]
MPPF-PET study. Brain 2004;127(4):900–1013.
58. Boison D. Adenosine kinase, epilepsy and stroke: mechanisms and therapies.
Trends in Pharmacological Sciences 2006;27(12):652–8.
59. Carrier EJ, Auchampach JA, Hillard CJ. Inhibition of an equilibrative nucleoside
transporter by cannabidiol: a mechanism of cannabinoid immunosuppression.
Proceedings of the National Academy of Sciences of the United States of America
2006;103(20):7895–900.
60. Izzo AA, Borrelli F, Capasso R, Di Marzo V, Mechoulam R. Non-psychotropic
plant cannabinoids: new therapeutic opportunities from an ancient herb.
Trends in Pharmacological Sciences 2009;30(10):515–27.
